Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)
NCT ID: NCT00002186
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
400 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crofelemer
Acyclovir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* AIDS, according to the CDC criteria.
* Documented recurrent (at least 1 prior episode) perineal (genital, perianal and neighboring areas) mucocutaneous herpes simplex virus (HSV) types 1 or 2 infection in the active phase.
* Duration of current episode of recurrent HSV lesions of 3 days or less.
* Ability to read and write, must be intellectually competent, and able to understand the purposes and risks of the study.
Exclusion Criteria
Patients with the following symptoms and conditions are excluded:
* Active internal anal or rectal herpes.
* Inability to comply with protocol.
* Impaired renal function.
Patients with the following prior conditions are excluded:
* Prior episode of recurrent genital herpes infection with documented clinical failure of acyclovir as a treatment regimen.
* Uncompensated hepatic, cardiac, or renal failure within 1 month of the study.
* History of hypersensitivity to acyclovir.
* Previous enrollment in this study.
1\. Treatment with another medication (topical, oral, or intravenous) with known anti-HSV activity within the past 5 days.
* Systemic immunomodulatory therapy within 30 days prior to study.
* Previous treatment with SP-303.
Required:
Unchanged antiretroviral therapy for the 2 weeks prior to study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaman Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sorra Research Ctr Inc / Med Forum
Birmingham, Alabama, United States
Hill Top Research Ltd
Scottsdale, Arizona, United States
Arizona Clinical Research Ctr Inc
Tucson, Arizona, United States
Dermatology SVC - VAMC
Long Beach, California, United States
King - Drew Med Ctr / Dept of Dermatology
Los Angeles, California, United States
Summit Med Ctr / Adult Immunology Clinic
Oakland, California, United States
ViRx Inc
Palm Springs, California, United States
ViRx Inc
San Francisco, California, United States
Conant Med Ctr
San Francisco, California, United States
Olive View Med Ctr
Sylmar, California, United States
Novum Inc
Washington D.C., District of Columbia, United States
IDC Research Initiative
Altamonte Springs, Florida, United States
Gary Richmond MD
Fort Lauderdale, Florida, United States
Dr Robert Schwartz
Fort Myers, Florida, United States
Infectious Disease Research Institute Inc
Tampa, Florida, United States
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, United States
Veterans Affairs Med Ctr of North Chicago
Chicago, Illinois, United States
Johns Hopkins Univ / Division of Infectious Disease
Baltimore, Maryland, United States
Saint Agnes Healthcare / Dept of Surgery
Baltimore, Maryland, United States
Massachusetts Gen Hosp - Warren 505
Boston, Massachusetts, United States
Medicine / Infectious Diseases
Minneapolis, Minnesota, United States
AIDS Ctr / Saint Vincents Hosp and Med Ctr
New York, New York, United States
New York Univ Med Ctr
New York, New York, United States
Mount Sinai Med Ctr
New York, New York, United States
Columbia Presbyterian Med Ctr
New York, New York, United States
Paddington Testing Co Inc
Philadelphia, Pennsylvania, United States
Austin Infectious Disease Consultants
Austin, Texas, United States
N Texas Ctr for AIDS & Clin Rsch
Dallas, Texas, United States
Division of Infectious Diseases / Univ of Texas - Houston
Houston, Texas, United States
Dr Robert Holman
Arlington, Virginia, United States
Novum Inc
Seattle, Washington, United States
Univ of Washington Virology Research Clinic
Seattle, Washington, United States
Hosp Regional de Ponce - Area Vieja
Ponce, , Puerto Rico
San Juan AIDS Program
Santurce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
96-867-DE
Identifier Type: -
Identifier Source: secondary_id
270A
Identifier Type: -
Identifier Source: org_study_id